81 results
Page 3 of 5
425
q7stgjt9ttj38yl4z7o
11 Jan 21
Business combination disclosure
10:50am
425
y5lt2di0w4 oiv
5 Jan 21
Business combination disclosure
9:36am
8-K
EX-2.1
qoryoopbqtuaf
15 Dec 20
Anchiano Therapeutics and Chemomab Announce Entry Into
3:34pm
8-K
EX-99.1
rtz3 ob6bzi
15 Dec 20
Anchiano Therapeutics and Chemomab Announce Entry Into
3:34pm
8-K
xv6dvovl affis2ssx
15 Dec 20
Anchiano Therapeutics and Chemomab Announce Entry Into
3:34pm
DEFA14A
EX-99.1
ldmdat wwt50f
15 Dec 20
Additional proxy soliciting materials
3:32pm
DEFA14A
EX-2.1
tygm154c783royipl9n
15 Dec 20
Additional proxy soliciting materials
3:32pm
DEFA14A
g1bgb4d w0s
15 Dec 20
Additional proxy soliciting materials
3:32pm
10-Q
zucfhtkkh5p8v9qvuw
7 May 20
Quarterly report
4:37pm
10-K
uu3 1aha65u5tx
17 Mar 20
Annual report
5:27pm
6-K
EX-10.1
zf912
23 Sep 19
Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/β-catenin Inhibitor Programs
5:29pm
S-8
EX-99.2
17aymbx ivaag71hk
22 Jul 19
Registration of securities for employees
5:17pm
20-F/A
3b73rgdp0
24 Apr 19
Annual report (foreign) (amended)
5:19pm
6-K
EX-1.1
hupekf
14 Feb 19
Current report (foreign)
4:40pm
424B4
o20hdu4ea1eshivq7asb
13 Feb 19
Prospectus supplement with pricing info
8:20am
F-1/A
j898ar 1paqj
11 Feb 19
Registration statement (foreign) (amended)
9:52am
F-1/A
EX-3.2
7tm1nzy9svr39k0 7tw
11 Feb 19
Registration statement (foreign) (amended)
9:52am